Your Cross-Border Biotech Partner
Empowering Biotech Innovation, Driving Global Growth
TAB Bio’s Rigorous Pipeline Selection
Every therapeutic candidate showcased in our pipeline has been rigorously screened, scientifically vetted, and evaluated for development feasibility through TAB Bio’s multi‑disciplinary due‑diligence platform. Only the assets that satisfy our stringent criteria for mechanism validity, manufacturability, regulatory tractability, and commercial differentiation advance into active development.
Company Overview
TAB Bio is a next‑generation biotechnology company that accelerates the development of innovative therapies through a capital‑efficient, de‑risked model. Leveraging a systematic in‑licensing → development → out‑licensing strategy, we source high‑potential yet under‑developed assets, elevate them through decisive clinical milestones, and partner with leading pharmaceutical companies for global commercialization.
Our proprietary diligence engine assesses hundreds of opportunities annually, selecting only those with robust science, clear clinical rationale, and realistic paths to market. This disciplined approach enables us to optimize clinical pathways, mitigate regulatory risks, and unlock value rapidly and responsibly.
We focus on high‑impact therapeutic areas where unmet medical needs remain significant. By combining deep scientific expertise, operational excellence, and a model designed for capital efficiency, TAB Bio is redefining how novel therapeutics are discovered, developed, and delivered to patients worldwide.